Adrenergic and muscarinic receptor regulation and therapeutic implications in heart failure

Molecular and Cellular Biochemistry

Volumn 157, Issue 1-2, 1996, Pages 251-258

  Schmitz, Wilhelm ^a   Boknik, Peter ^a   Linck, Bettina ^a   Müller, Frank U ^a  

^a UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Adrenergic receptor; Angiotensin converting enzyme inhibitor; G protein; Heart failure; Muscarinic receptor; Phosphodiesterase inhibitor; adrenoceptor antagonist

Indexed keywords

5 [1 (3,4 DIMETHOXYBENZOYL) 1,2,3,4 TETRAHYDRO 6 QUINOLYL] 3,6 DIHYDRO 6 METHYL 2H 1,3,4 THIADIAZIN 2 ONE; ADENOSINE TRIPHOSPHATASE (CALCIUM); ADIBENDAN; AMRINONE; BETA 1 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; BUCINDOLOL; CALCIUM ION; CAPTOPRIL; CATECHOLAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOBUTAMINE; ENOXIMONE; INHIBITORY GUANINE NUCLEOTIDE BINDING PROTEIN; ISOMAZOLE; LISINOPRIL; METOPROLOL; MILRINONE; MUSCARINIC RECEPTOR; PHOSPHODIESTERASE; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLAMBAN; PIMOBENDAN; SULMAZOLE;

ADRENERGIC STIMULATION; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CLINICAL TRIAL; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CONTRACTILITY; HUMAN; INOTROPISM; RECEPTOR DOWN REGULATION; SARCOPLASMIC RETICULUM;

EID: 0030007448     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF00227907     Document Type: Article

References (91)

1. 2-adrenergic receptor-mediated adenylate cyclase stimulation in nonfailing and failing human ventricular myocardium. Mol Pharm 35: 295-303, 1989
2. Daly PA, Sole MJ: Myocardial catecholamines and the pathophysiology of heart failure. Circulation 82(suppl 1): I-35-143, 1990
3. Schmitz W, Scholz H, Erdmann E: Effects of alpha- and beta-adrenergic agonists, phosphodiesterase inhibitors and adenosine on isolated human heart muscle preparations. Trends Pharmacol Sci 8: 447-450, 1987
4. Eschenhagen T: G proteins and the heart. Cell Bioi Int 17(8): 723-749, 1993
5. Bristow MR, Anderson FL, Port DP, Skerl L, Hershberger KS, Larabee P, O Connell JB, Reniund DG, Volkman K, Murray J, Feldman AM: Differences in b-adrenergic neuroeffector mechanisms in ischemic versus idiopathic dilated cardiomyopathy. Circulation 84: 1024-1039, 1991
6. Böhm M, Gierschik P, Jakobs K-H, Pieske B, Schnabel P, Ungerer M, Erdmann E: Increase of Giα in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249-1265, 1990
7. 2-adrenoceptors in the human heart: Properties, function, and alterations in chronic heart failure. Pharmacol Rev 43: 203-242, 1991
8. 2-adrenoceptors in different human heart diseases. Naunyn-Schmiedeberg's Arch Pharmacol 343: 217-220, 1991
9. Swedberg K, Eneroth P, Kjekshus J, Wilhelmsen L: Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. Circulation 82: 1730-1736, 1990
10. 1-adrenergic receptors in the failing human heart. Circulation 87: 454-463, 1993
11. Linder ME, Gilman AG: G proteins. Scientific American July 1992: 36-43
12. + channels. Cell 61: 769-776, 1990
13. Fleming JW, Wisler PL, Watanabe AM: Signal transduction by G proteins on cardiac tissues. Circulation 85: 420-433, 1992
14. Brown AM: A cellular logic for G-protein coupled ion channel pathways. FASEB J 5: 2175-2179, 1991
15. Katz AM: Physiology of the heart. 2nd ed.. Raven Press, New York, 1992
16. Feldman MD, Copelas L, Gwathmey JK, Phillips P, Warren SE, Schoen FJ, Grossman W, Morgan JP: Deficient production of cyclic AMP: pharmacologic evidence of an important cause of contractile dysfunction in patients with endstage heart failure. Circulation 75: 331-339, 1987
17. Feldman AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL; Baumgartner WA, van Dop C: Increase in the 40,000-mol wt pertussis toxin substrate (G-protein) in the failing human heart. J Clin Invest 82: 189-197, 1988
18. Schnabel P, Böhm M, Gierschik P, Jakobs KH, Erdmann E: Improvement of cholera toxin-catalysed ADP-ribosylation by endogenous ADP-ribosylation factor from bovine brain provides evidence for an unchanged amount of Gsα in failing human myocardium. J Mol Cell Cardiol 22: 73-82, 1990
19. Neumann J, Schmitz W, Scholz H, von Meyerinck L, Döring V, Kalmár P: Increase of myocardial Gi-proteins in human heart failure. Lancet II: 936-937, 1988
20. Böhm M, Eschenhagen T, Gierschik P, Larisch K, Lensche H, Mende U, Schmitz W, Schnabel P, Scholz H, Steinfath M, Erdmann E: Radioimmunological quantification of Gi alpha in right and left ventricles from patients with ischaemic and dilated cardiomyopathy and predominant left ventricular failure. J Mol Ceil Cardiol 26: 133-149, 1994
21. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Haverich A, Hirt S, Doring V, Kalmár P, Höppner W, Seitz HJ: Increased messenger RNA level of the inhibitory G-protein a subunit Giα-2 in human end-stage heart failure. Circ Res 70: 688-696, 1992
22. Mende U, Eschenhagen T, Geertz B, Schmitz W, Scholz H, Schulte am Esch J, Sempell R, Steinfath M: Isoprenaline-induced increase in the 40/41 kDa pertussis toxin substrates and functional consequences on contractile response in rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 345: 44-50, 1992
23. Eschenhagen T, Mende U, Diederich M, Nose M, Schmitz W, Scholz H, Schulte am Esch J, Warnholtz A, Schöfer H: Long-term β-adrenoceptor mediated upregulation of Giα and Goα mRNA levels and pertussis toxin-sensitive guanine nucleotide-binding proteins in rat heart. Mol Pharm 42: 773-783, 1992
24. Müller FU, Boheler KR, Eschenhagen T, Schmitz W, Scholz H: Isoprenaline stimulates gene transcription of the inhibitory G-protein α-subunit Giα-2 in rat heart. Circ Res 72: 696-700, 1993
25. 2-muscarinic receptors in the human right atrium. Br J Pharmacol 101 (2): 363-369, 1990
26. Jakob H, Sigmund M, Beck F, Hanrath P, Eschenhagen T, Geertz B, Scholz H, Steinfath M: Reduction of Giα in myocardial biopsies of patients with heart failure under metoprolol treatment. Circulation 90: I-413, 1994
27. Eschenhagen T, Mende U, Nose M, Schmitz W, Scholz H, Warnholtz A, Wustel JM: Isoprenaline-induced increase in mRNA levels of inhibitory G-protein α-subunits in rat heart. Naunyn-Schmiedeberg's Arch Pharmacol 343:609-615,1991
28. 2 gene transcriptional activity in rat heart. J Mol Cell Cardiol 26: 869-875, 1994
29. Gwathmey JK, Copelas L, Makinnon R, Shoen FJ, Feldman MD, Grossman W, Morgan JP: Abnormal intracellular calcium handling in myocardium from patients with end-stage heart failure. Circ Res 61: 70-76, 1987
30. Limas CJ, Olivari M-T, Goldenberg TB, Benditt DG, Simon A: Calcium uptake by cardiac sarcoplasmic reticulum in human dilated cardiomyopathy. Cardiovasc Res 21: 601-605, 1987
31. Movsesian MA, Bristow MR, Krall J: Calcium uptake by cardiac sarcoplasmic reticulum from patients with dilated cardiomyopathy. Circ Res 65: 1141-1144, 1989
32. 2+ uptake in cardiac sarcoplasmic reticulum from normal and failing human hearts. J Clin Invest 85: 1698-1702, 1990
33. 2+-AT-Pase genes: homologies and mechanistic implications of deduced amino acid sequences. Cell 44: 597-607, 1986
34. 2+ pump. J Biol Chem 264: 18561-18568, 8919
35. 2+-dependent ATPase from rabbit muscle sarcoplasmic reticulum, deduced from ist complementary DNA sequence. Nature 316: 696-700, 1985
36. Jones LR: Sarcolemmal enzymes mediating β-adrenergic effects in the heart. In: F. A. Bronner, A. E. Shamoo AE (eds). Current topics in membranes and transport; regulation of calcium transport across muscle membranes. Academic Press, New York, 1985, pp 11-41
37. 2+ ATPase gene expression in the human ventricle during end-stage heart failure. J Clin Invest 85: 305-309, 1990
38. Arai M, Alpert NR, MacLennan DH, Barton P, Periasamy M: Alterations in sarcoplasmic reticulum gene expression in human heart failure: a possible mechanism for alterations in systolic and diastolic properties of the failing myocardium. Circ Res 72: 463-469, 1993
39. 2+-transporting ATPase, phospholamban and calsequestrin levels in nonfailing and failing human heart. Circulation 90: 653-657, 1994
40. 2+-ATPase in failing and nonfailing myocardium. Circ Res 75: 434-442, 1994
41. Luo W, Grupp IL, Harrer J, Ponniah S, Grupp G, Duffy JJ, Doetschman T, Kranias EG: Targeted ablation of the phospholamban gene is associated with markedly enhanced myocardial contractility and loss of β-agonist stimulation. Circ Res 75: 401-409, 1994
42. Danielsen W, von der Leyen H, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Döring V, Kalmár P: Basal and isoprenaline-stimulated cAMP content in failing versus nonfailing human cardiac preparations. J Cardiovasc Pharmacol 14: 171-173, 1989
43. Böhm M, Reiger B, Schwinger RH, Erdmann E: cAMP concentrations, cAMP dependent protein kinase activity, and phospholamban in nonfailing and failing myocardium. Cardiovasc Res 28(11): 1713-1719, 1994
44. Shenolikar S, Nairn AC: Protein phosphatases: recent progress. In: P. Greengard and G. A. Robison (eds). Advances in second messenger and phosphoprotein research. Raven Press, New York, 1991, pp 1-121
45. Neumann J, Eschenhagen T, Jones LR, Linck B, Schmitz W, Scholz H, Zimmermann N: Increased expression of cardiac phosphatases in patients with endstage heart failure. 1995 (submitted)
46. Deighton NM, Motomura S, Borquez D, Zerkowski H-R, Doetsch N, Brodde O-E: Muscarinic cholinoceptors in the human heart: demonstration, subclassification, and distribution. Naunyn-Schmiedebergs's Arch Pharmacol 341: 14-21, 1990
47. Kohl C, Schmitz W, Scholz H: Positive inotropic effect of carbachol and inositol phosphate levels in mammalian atria after pretreatment with pertussis toxin. J Pharmacol Exp Ther 254: 894-899, 1990
48. Brückner R, Fenner A, Meyer W, Nobis T-M, Schmitz W, Scholz H: Cardiac effects of adenosine and adenosine analogs in guinea-pig atrial and ventricular preparations: evidence against a role of cyclic AMP and cyclic GMP: J Pharmacol Exp Ther 234: 766-774, 1985
49. Brovvn AM, Birnbaumer L: Ionic channels and their regulation by G protein subunits. Annu Rev Physiol 52: 197-213, 1990
50. Gilman AG: G proteins and dual control of adenylate cyclase. Cell 36: 577-579, 1984
51. Gupta RC, Neumann J, Boknik P, Watanabe AM: M2-specific muscarinic cholinergic receptor-mediated inhibition of cardiac regulatory protein phosphorylation. Am J Physiol 266: H1138-H1144, 1994
52. Neumann J, Boknik P, Bodor GS, Jones LR, Schmitz W, Schoiz H: Effects of adenosine receptor and muscarinic cholinergic receptor agonists on cardiac protein phosphorylation. J Pharmacol Exp Ther 269: 1310-1318: 1994
53. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc Natl Acad Sci USA 88: 1197-1201, 1991
54. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J Biol Chem 268: 26286-26295, 1993
55. Ahmad Z, Green FJ, Subuhi HS, Watanabe AM: Autonomic regulation of type 1 protein phosphatase in cardiac muscle. J Biol Chem 264: 3859-3863, 1989
56. Neumann J, Kaspareit G, Scholz H: Fluoride ion attenuates the negative inotropic effects of muscarinic M2 and adenosine receptor agonists. Eur J Pharmacol, in press, 1995
57. 2+ channels. Pflüger's Arch - Eur J Physiol 429: 531-538, 1995
58. Böhm M, Ungerer M, Erdmann E: Adenosine receptors in the human heart: Pharmacological characterization in nondiseased and cardiomyopathic tissue. Drug Develop Res 28: 268-276, 1993
59. von der Leyen H, Mende U, Meyer W, Neumann J, Nose M, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Doring V, Kalmar P, Haverich A: Mechanism underlying the reduced positive inotropic effects of the phosphodiesterase inhibitors pimobendan, adibendan and saterinone in failing as compared to nonfailing human cardiac muscle preparations. Naunyn-Schmiedeberg's Arch Pharmacol 344: 90-100, 1991
60. Schmitz W, Eschenhagen T, Mende U, Muller FU, Neumann J, Scholz H: Phosphodiesterase inhibition and positive inotropy in failing human myocardium. In: G. Hasenfuss, Ch. Holubarsch, H. Just and N. R. Alpert (eds). Cellular and Molecular Alterations in the Failing Human Heart. Steinkopff Verlag, Darmstadt, 1992, pp 65-71
61. Bethke T, Klimkievvicz A, Kohl C, von der Leyen H, Mehl H, Mende U, Meyer W, Neumann J, Schmitz W, Scholz H, Starbatty J, Stein B, Wenzlaff H, Döring V, Kalmar P, Haverich A: Effects of isomazole on force of contraction and phosphodiesterase isoenzymes in nonfailing and failing human hearts. J Cardiovasc Pharmacol 18: 386-397, 1991
62. Bethke T, Eschenhagen T, Klimkie\,vicz A, Kohl C, von der Leyen H, Mehl H, Mende U, Neumann J, Rossvvag S, Schmitz W, Scholz H, Slarbatty J, Stein B, Wenzlaff H, Döring V, Kalmár P, Haverich A: Phosphodieslerase inhibilion by enoximone in preparations from failing and nonfailing human hearts. Arzneimittel Forsch 42: 437-445, 1992
63. Levine TB, Francis GS, Goldsmith SR, Simon AB, Cohn JN: Activity of the sympathetic nervous system and renin-angiotensin system assesed by plasma hormone levels and their relation to hemodynamic abnormalities in congestive heart failure. Am J Cardiol 49: 1659-1666, 1982
64. Gage J, Rutman H, Lucido D, LeJemtel TH: Additive effects of dobutamine and amrinone on myocardial contractility and ventricular performance in patients with severe heart failure. Circulation 74: 367-373, 1986
65. Colucci WS: Observations on the intracoronary administration of milrinone and dobulamine to patients with congestive heart failure. Am J Cardiol 63: 17-22, 1989
66. Gilbert EM, Port JD, Hershberger RE, Bristow MP: Clinical significance of alterations in the β-adrenergic receptor-adenylate cyclase complex in heart failure. Heart Failure 5: 91-98, 1989
67. Packer M, Medina M, Yushak M: Hemodynamic and clinical limitations of longterm inotropic therapy with amrinone in patients with severe chronic heart failure. Circulation 70: 1038-1047, 1984
68. Uretsky BF, Jessup M, Konstam MA, Dec GW, Leier CV, Benotti J, Muralli S, Herrmann HC, Sandberg JA: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82: 774-780, 1990
69. The CONSENSUS Trial Study Group: Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 316: 1429-1435, 1987
70. Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, Hendrix GH, Bommer WJ, Elkayam U, Kukin ML, Mallis Gl, Sollano JA, Shannon J, Tandon PK, Demets DL: Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468-1475, 1991
71. Packer M: Pathophysiology of chronic heart failure. Lancet 340: 88-92, 1992
72. Rüegg JC, Solaro RJ: Calcium-sensitizing positive inotropic drugs. In: J.K. Gwathmey, G.M. Briggs and P.D. Allen (eds). Heart Failure: Basic Science and Clinical Aspects. Marcell Dekker, Inc., New York, 1993, pp 457-473
73. Captopril Multicenter Research Group: A placebo-controlled trial of captopril in refractory chronic congestive heart failure. J Am Coll Cardiol 2: 755-763, 1983
74. The SOLVD Investigators: Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 325: 293-302, 1991
75. The SOLVD Investigators: Effect on enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 327: 685-691, 1992
76. The SAVE Investigators: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669-677, 1992
77. The AIRE Investigators: Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. Lancet 3452: 821-882, 1993
78. Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR: Assessment of the β-adrenergic receptor pathway in the intact failing human heart: progressive receptor downregulation and subsenssitivity to agonist response. Circulation 74: 1290-1302, 1986
79. Gilbert EM, Sandoval A, Larrabee P, Reniund DG, O Connell JB, Bristow MR: Lisinopril lowers cardiac adrenergic drive and increases β-adrenoceptor density in the failing human heart. Circulation 88:472-480, 1993
80. Jakob H, Sigmund M, Eschenhagen T, Mende U, Patten M, Schmitz W, Scholz H, Schulte am Esch J, Steinfath M, Hanrath P, Völker H: Effect of captopril on myocardial β-adrenoceptor density and Giα-proteins in patients with mild to moderate heart failure due to dilated cardiomyopathy. Eur J Clin Pharmacol 47: 389-394, 1994
81. Hjalmarson A, Waagstein F: New therapeutic strategies in chronic heart failure: Challenge of long-term beta-blockade. Eur Heart J 12(Suppl F): 63-69, 1991
82. Eichhorn EJ: The paradox of beta-adrenergic blockade for the management of congestive heart failure. Am J Med 92:527-538, 1992
83. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group: Waagstein F, Bristow MR, Swedberg K, Camerini F, Fowler MB, Silver MA, Gilbert EM, Johnson MR, Goss FG, Hjalmarson A: Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Lancet 342: 1441-1446, 1993
84. Fisher ML, Gottlieb SS, Plotnick GD, Greenberg NL, Patten RD, Bennett SK, Hamilton BP: Beneficial effects of metoproiol in heart failure associated with coronary artery disease: a randomized trial. J Am Coll Cardiol 23: 943-950, 1994
85. A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees. Circulation 90(4): 1765-1773, 1994
86. Bristow MR, O Connell JB, Gilbert EM, French WJ, Leatherman G, Kantrowitz NE, Orie J, Smucker ML, Marshall G, Kelly P et al. for the Bucindolol Investigators: Dose-response of chronic beta-blocker treatment in heart failure from either idiopathic dilated or ischemic cardiomyopathy. Circulation 89(4): 1632-1642, 1994
87. Eichhorn EJ, Heesch CM, Risser RC, Marcoux L, Hatfield B: Predictors of systolic and diastolic improvement in patients with dilated cardiomyopathy treated with metoprolol. J Am Coll Cardiol 25(1): 154-162, 1995
88. Eichhorn EJ, McGhie I, Bedotto JB, Corbett JR, Malloy CR, Hatfield BA, Deitchman D, Willard JE, Grayburn PA: Effects of bucindolol on neurohumoral activation in congestive heart failure. Am J Cardiol 676: 67-73, 1991
89. Chadda K, Goldstein S, Byington R, Curb JD: Effect of propranolol after acute myocardial infarction in patients with congestive heart failure. Circulation 73: 503-510, 1986
90. Katz AM: Cell death in the failing heart: role of an unnatural growth response to overload. Clin Cardiol, in press, 1995
91. Müller FU, Boknik P, Horst A, Knapp J, Linck B, Schmitz W, Vahlensieck U, Böhm M, Deng MC, Scheld HH: The cAMP response element binding protein (CREB) is expressed and phosphorylated in the human heart. Circulation, in press, 1995